Table 2.
Clinical information of 52 TTS case reports with complete anti-PF4 antibody test results.
| Item | Measure | Non-survivors | Survivors | p-value |
|---|---|---|---|---|
| TTS | Total number | 12 | 40 | – |
| Platelet Count, Nadir [platelets/µl] | Median IQR |
15,000 10,000 - 18,000 |
49,000 27,000 - 64,000 |
<0·0001 |
| D-Dimer [mg/L] |
Median IQR number assessed |
24·8 20·0 – 36·0 9 |
30·7 17·0 – 35·0 27 |
0·75 |
| Age [years] | Median IQR |
49·0 35·5 – 62·0 |
44·5 29·0 – 59·5 |
0·45 |
| Sex [Female] | number [%] | 7 [58] | 30 [75] | 0·44 |
| CVST | number [%] | 10 [83] | 27 [68] | 0·50 |
| Multiple thrombosis | number [%] | 7 [58] | 12 [30] | 0·15 |
| Time to onset [days] | Median IQR |
9·0 7·5 – 11·0 |
10·0 7·0 – 12·0 |
0·86 |
Abbr: TTS Thrombosis with thrombocytopenia; CVST cerebral venous sinus thrombosis; IQR interquartile range.